Benjamin Izar is a consultant for or received honoraria from Volastra Therapeutics, Johnson & Johnson/Janssen, Novartis, GSK, Eisai, AstraZeneca and Merck, and has received research funding to ...

To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved ...

To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved Alzheimer’s disease drugs are too small to justify the costs. Neither Kisunla ...

The agency maintains that the beta-amyloid-targeting drugs show too limited benefit to justify their cost to the National Health Service.

In a first for the bloc, Europe’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing ...

And other biotech news brought to you by The Readout.

Matcha, a vibrant green tea powder with ancient Japanese roots, has exploded in popularity worldwide. From traditional tea ...

And more pharma news updates from Pharmalittle.

Eli Lilly (NYSE:LLY) announced it would appeal a decision by the U.K. health authorities not to recommend the company’s new ...